Summary of AptarGroup FY Conference Call (March 03, 2026) Company Overview - **Company**: AptarGroup (NYSE:ATR) - **Industry**: Drug and consumer product packaging - **Core Business**: Design and manufacturing of dosing, dispensing, and protection technologies, with a focus on proprietary intellectual property [3][4] Financial Performance - **2025 Revenue**: Approximately $3.8 billion - **Pharma Segment**: 46% of revenue, 70% of adjusted EBITDA - **Beauty Segment**: 35% of revenue, 18% of adjusted EBITDA - **Closures Segment**: 19% of revenue, 13% of adjusted EBITDA [4] - **Capital Return**: $1.2 billion returned to shareholders over the last five years through dividends and share buybacks [6][14] - **Leverage Ratio**: 1.38x EBITDA, at the low end of the 1-3x corridor [5] Market Segments and Growth Opportunities - **Pharma Segment**: - Total Addressable Market (TAM): $165 billion, projected 7% CAGR - Revenue CAGR over the last 10 years: 9% [11][22] - Key products: Proprietary drug delivery systems (70% of pharma revenue), injectables (19%), active material science solutions (10%) [17] - Strong pipeline in respiratory, biologics, and systemic nasal drug delivery [24][25] - **Beauty Segment**: - Revenue: $1.3 billion in 2025, with 60% of sales in Europe - Growth: 7% total sales growth, 2% core sales growth [35][38] - Focus on innovation and serving both major and indie brands [38] - **Closures Segment**: - Revenue: $700 million, with 2% reported growth and 1% core growth [39] - Strong product volume growth of 4% when isolating resin pass-through impacts [41] Innovation and Technology - **Intellectual Property**: Over 7,300 patents, with 62% in pharma [10][18] - **Sustainability Leadership**: Recognized for sustainability efforts, which attract customers and talent [15][16] - **AI and Digital Health**: Incorporating AI for advanced analytics to enhance service offerings and strengthen customer relationships [53][54] Strategic Focus - **Investment Strategy**: Approximately two-thirds of capital returned to business through organic CapEx and M&A, with a focus on the pharma segment [13][14] - **Long-term Revenue Growth Target**: 4%-7% total revenue growth, supported by market growth projections [12][29] - **Customer Engagement**: Building relationships from the design phase through to patient engagement, enhancing revenue stickiness [30][32] Key Challenges and Considerations - **Emergency Medicine Reset**: Acknowledged impact on pharma growth, but overall strong growth in other areas [41] - **Market Dynamics**: Transition from high GWP to low GWP propellants in inhalers, with regulatory pressures influencing growth [46][47] Conclusion - **Outlook**: Positive growth trajectory across all segments, with a strong emphasis on innovation, sustainability, and leveraging technology to enhance customer value and operational efficiency [42][54]

Company Overview - TriMas is a diversified manufacturer with a global presence, focusing on packaging and aerospace fasteners, leveraging established brands and engineering expertise to meet evolving customer needs [6] - The company generates revenue primarily through the design, manufacture, and sale of proprietary and custom-engineered products for consumer, industrial, and aerospace applications [8] - Key customers include consumer product companies, aerospace original equipment manufacturers, industrial distributors, and commercial end-users worldwide [8] Financial Performance - TriMas reported revenue of $1.01 billion and net income of $44.08 million for the trailing twelve months (TTM) [4] - The company recently posted $269.3 million in third quarter sales, reflecting a 17.4% year-over-year increase, with adjusted diluted EPS rising 41.9% to $0.61 [10] - Adjusted operating profit increased 33.9% to $30.3 million, and year-to-date free cash flow reached $43.9 million, nearly quadrupling the prior year period [10] Stock Performance - As of February 12, 2026, shares of TriMas were priced at $35.75, up 51.4% over the past year, significantly outperforming the S&P 500 by 38.45 percentage points [7] - Following a sale of 143,900 shares, TriMas represents 3.05% of Barington Companies Management's reported U.S. equity assets under management [7] Market Position and Strategy - TriMas emphasizes innovation in its product lines and operational efficiency, supporting a competitive position in the packaging and industrial components sectors [6] - The company is positioned to benefit from aerospace and industrial recovery, with a focus on sustaining momentum in these sectors [11]

Core Sales Performance - Pharma core sales increased by 4% in the quarter, with prescription core sales growing by 1%, driven by systemic nasal drug delivery and higher royalty payments, despite a 36% decline in emergency medicine sales [1][5][19] - For the quarter ended December 31, 2025, Aptar reported sales of $963 million, a 14% increase from $848 million a year earlier, with core sales reflecting healthy underlying demand across all segments [4][5] Profitability and Financial Metrics - Adjusted EPS for the quarter was $1.25, down from $1.62 in the prior year, attributed to higher depreciation, amortization, and interest expenses [2] - Adjusted EBITDA was $191 million, a 2% decrease year-over-year, with an adjusted EBITDA margin of 19.8%, down from 23% in the prior-year quarter, impacted by unfavorable product mix and higher production costs [3][7] Segment Performance - Injectables core sales increased by 24%, driven by demand for elastomeric components, while consumer healthcare core sales rose by 3% [10] - Beauty segment achieved 10% core sales growth, with personal care growing by 17%, although the adjusted EBITDA margin decreased to 10.2% due to lower-margin projects and operational disruptions [9][12] Capital Allocation and Shareholder Returns - In 2025, the company returned $486 million to shareholders through dividends and share repurchases, with a new $600 million buyback authorization announced [15][16] - Free cash flow was reported at $303 million, down $64 million year-over-year, primarily due to timing of tax payments and higher working capital [14] Outlook and Challenges - For Q1 2026, adjusted EPS is guided to be between $1.13 and $1.21, reflecting higher interest expenses and an expected effective tax rate of 21% to 23% [18] - Management anticipates a $65 million revenue headwind in 2026 due to declining emergency medicine demand, with the impact expected to be more pronounced in the first half of the year [19][20]

Company Overview - Amcor develops and produces a wide range of packaging products, including flexible packaging, rigid packaging containers, specialty cartons, and closures, operating across more than 200 sites in 40 countries [1] - BHP Group, founded in 1885, is a diversified natural resources company focused on mineral exploration and production, with key areas in copper and related minerals, iron ore, and coal [3] Financial Performance - The share price of Amcor (ASX:AMC) has decreased by approximately 17.6% since the start of 2025, while BHP's share price is 37.6% above its 52-week low [1] - Amcor's current dividend yield is around 5.98%, which is higher than its 5-year average of 4.38%, indicating potential growth in dividends [6] - BHP offers a historical dividend yield of approximately 4.78%, compared to its 5-year average of 6.86%, suggesting a decline in dividend yield relative to historical performance [7] Investment Characteristics - Amcor is focused on innovation in sustainable packaging to meet changing consumer and regulatory demands [2] - BHP is regarded as a stable, dividend-paying investment and is commonly included in ASX share portfolios, indicating its attractiveness to investors [4]

Core Insights - TriMas is divesting its aerospace division to focus on its packaging business, which is its largest segment [2][6] - The aerospace segment is being sold for approximately $1.45 billion to a subsidiary of Tinicum, with the deal expected to close by the end of Q1 2026 [2] - The new CEO, Thomas Snyder, emphasized a strategy centered around a high-margin packaging platform and plans for targeted acquisitions to drive growth [2][3] Company Strategy - TriMas aims to unify its branding within the packaging business by consolidating over six legacy brands into a single, cohesive brand [4] - The company reported net sales of $269.3 million in Q3, with packaging contributing $135.7 million, reflecting a 4.2% year-over-year increase driven by growth in beauty and personal care dispensers [5] - The company has previously indicated a review of its portfolio, having exited the oil and gas market by selling its Arrow Engine business [6] Industry Context - Other major packaging manufacturers are also refining their focus, such as Sonoco's sale of its temperature-controlled solutions business for up to $725 million and International Paper's pending sale of its global cellulose fibers business [6] - Ball, another significant player in the packaging industry, sold its aerospace business for $5.6 billion to BAE Systems [7]

Core Insights - Amcor plc will announce its First Quarter 2026 results on November 5, 2025, after the US market closes [1] - A conference call and webcast to discuss the results will take place at 5:30 PM US Eastern Standard Time on the same day [1] - Amcor is a global leader in responsible consumer packaging and dispensing solutions, generating $23 billion in annualized sales from over 400 locations in more than 40 countries [1] Company Overview - Amcor specializes in packaging solutions for nutrition, health, beauty, and wellness categories [1] - The company focuses on product innovation and sustainability to address packaging challenges globally [1] - Amcor employs over 75,000 people and is committed to safety and sustainability in its operations [1]

Leadership Transition - Michael Casamento will leave Amcor to return to Australia, remaining in an advisory role until June 30, 2026, to support the transition [1][3] - Stephen R. Scherger has been appointed as the new Executive Vice President and Chief Financial Officer, effective November 10, 2025 [1][3] Executive Background - Stephen R. Scherger has over 30 years of experience in finance, operations, and strategy within the packaging industry, previously serving as CFO of Graphic Packaging [2][5] - Under Scherger's leadership, Graphic Packaging's net sales more than doubled to nearly $9 billion, and net income nearly tripled during his tenure [2] Company Outlook - Amcor reaffirmed its fiscal year 2026 outlook, expecting Adjusted EPS of 80-83 cents per share, representing 12-17% constant currency growth, and Free Cash Flow of $1.8-1.9 billion [4] - For the first quarter of fiscal year 2026, Amcor anticipates Adjusted EPS to be within the previously announced range of 18-20 cents per share [4] CEO Comments - Amcor CEO Peter Konieczny expressed confidence in Scherger's ability to enhance growth and profitability, highlighting his industry experience and leadership style [3] - Konieczny thanked Casamento for his decade of service, noting that Amcor is well-positioned following the successful combination with Berry Global [3] Company Profile - Amcor is a global leader in responsible consumer packaging and dispensing solutions, generating $23 billion in annualized sales from operations across over 400 locations in more than 40 countries [6]

Company Overview - AptarGroup is a global supplier of innovative dispensing, sealing, and active packaging solutions for various markets including beauty, personal care, home care, prescription drugs, consumer health care, injectables, food, and beverages [12] - The company manufactures products such as dispensing pumps, closures, aerosol valves, and elastomeric primary packaging components, with facilities located in North America, Europe, Asia, and South America [12] Investment Analysis - AptarGroup currently holds a Zacks Rank of 3 (Hold) and has a VGM Score of B, indicating a solid position in the market [13] - The company is projected to experience year-over-year earnings growth of 4.3% for the current fiscal year, supported by upward revisions in earnings estimates from three analysts in the last 60 days [13] - The Zacks Consensus Estimate for AptarGroup's earnings has increased by $0.01 to $5.88 per share, with an average earnings surprise of +8.3% [13][14]

Financial Data and Key Metrics Changes - Consolidated net sales for Q2 2025 reached $275 million, up more than 14% year over year, with organic growth exceeding 13% [14][15] - Consolidated operating profit increased by over 50% compared to Q2 2024, reflecting strong revenue growth and a 300 basis point expansion in operating margin [15] - Adjusted EBITDA rose 31% to nearly $48 million, with a margin improvement of 220 basis points to 17.4% [15] - Adjusted earnings per share increased to $0.61, representing a 42% growth year over year [15] Business Line Data and Key Metrics Changes Packaging Segment - Achieved organic sales growth of nearly 8%, driven by strong demand for dispensers in the Beauty and Personal Care market [18] - Operating profit margin improved by 30 basis points to 14.3%, with adjusted EBITDA margin up 70 basis points to 20.9% [18] Aerospace Segment - Recorded sales of approximately $100 million, with a growth rate of over 32% [20] - Operating profit nearly doubled year over year, with margin expansion of 650 basis points [21] Specialty Products Segment - North Cylinder experienced 13% year-over-year sales growth, but overall sales in the segment were down 6.8% due to the divestiture of AeroEngine [22] - Operating profit more than doubled, with a margin improvement of 250 basis points year over year [22] Market Data and Key Metrics Changes - The Aerospace group benefited from increased demand in the aerospace and defense market, leading to a strong order book and improved throughput [20][21] - The Packaging segment is monitoring the evolving global tariff environment, which poses challenges but is being managed through strategic sourcing and pricing adjustments [19] Company Strategy and Development Direction - The new CEO emphasized the importance of operational improvements, cost efficiencies, and growth through internal and external investments [11][12] - Focus on greater standardization across global operations to enhance efficiency and reduce complexity [11] - Commitment to integrating recent acquisitions to unlock their full potential and drive profitable growth [12] Management's Comments on Operating Environment and Future Outlook - Management raised the 2025 sales growth outlook to 8-10% and adjusted earnings per share guidance to $1.95 to $2.10, reflecting strong performance in Aerospace and positive trends in Specialty Products [25] - The company remains cautious about the changing tariff environment, which could impact customer order patterns and consumer demand [25] Other Important Information - The company reported a decline in net debt and improved free cash flow, indicating a strong capital position [17] - The CEO's early observations highlighted the talent and dedication of the workforce, as well as the innovative capabilities of the products and processes [10] Q&A Session Summary Question: What does the portfolio look like over the intermediate to longer term? - The CEO indicated a focus on maximizing the current portfolio and operational improvements, with an emphasis on integrating and optimizing existing businesses [36][38] Question: Is there a moderation in operating leverage for aerospace in the back half of the year? - Management confirmed that seasonal trends and unique customer benefits in Q4 would lead to a moderation in operating margins [39][40] Question: How much of the aerospace growth is due to competitor capacity loss versus market share gains? - Management stated that competitive issues had a minimal impact on growth, attributing success to market penetration and new customer acquisitions [46] Question: Are bottleneck issues in packaging resolved? - Management acknowledged ongoing opportunities for improvement in the packaging segment, with initiatives in place to enhance efficiencies [49] Question: What is the expected new accounts receivable run rate? - Management indicated that accounts receivable are currently on the high side but improvements are expected over time [53]